Technical Analysis for INMB - INmune Bio Inc.

Grade Last Price % Change Price Change
D 15.37 -18.37% -3.46
INMB closed down 18.37 percent on Thursday, March 4, 2021, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical INMB trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Crossed Above 50 DMA Bullish -18.37%
Wide Bands Range Expansion -18.37%
Up 3 Days in a Row Strength -18.37%
Older End-of-Day Signals for INMB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 1 hour ago
Trending on StockTwits about 2 hours ago
Lower Bollinger Band Support about 6 hours ago
Down 2 ATRs about 6 hours ago
Fell Below Lower Bollinger Band about 7 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Immune System Disease Immunotherapy Cancer Treatments Precision Medicine Hematologic Malignancies Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Mdsc Residual Disease

Is INMB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 29.99
52 Week Low 2.2
Average Volume 343,703
200-Day Moving Average 11.30
50-Day Moving Average 18.87
20-Day Moving Average 18.86
10-Day Moving Average 17.32
Average True Range 1.92
ADX 22.9
+DI 19.56
-DI 32.70
Chandelier Exit (Long, 3 ATRs ) 19.32
Chandelier Exit (Short, 3 ATRs ) 20.39
Upper Bollinger Band 22.59
Lower Bollinger Band 15.13
Percent B (%b) 0.03
BandWidth 39.53
MACD Line -0.64
MACD Signal Line -0.32
MACD Histogram -0.32
Fundamentals Value
Market Cap 206.69 Million
Num Shares 13.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -24.87
Price-to-Sales 0.00
Price-to-Book 2.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.61
Resistance 3 (R3) 22.06 20.43 20.57
Resistance 2 (R2) 20.43 18.84 20.21 20.22
Resistance 1 (R1) 17.90 17.86 17.09 17.45 19.88
Pivot Point 16.27 16.27 15.86 16.05 16.27
Support 1 (S1) 13.74 14.68 12.93 13.29 10.86
Support 2 (S2) 12.11 13.70 11.89 10.52
Support 3 (S3) 9.58 12.11 10.17
Support 4 (S4) 9.13